OCUGEN, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
OCUGEN, INC. (OCGN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$66.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-04
- OCUGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$66.03M.
- OCUGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$53.64M.
- OCUGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2018 was -$8.50M.
- OCUGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2017 was -$26.27M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$66.03M 10-K · filed 2026-03-04 | |
| 2024-12-31 | -$53.64M 10-K · filed 2026-03-04 | |
| 2018-12-31 | -$8.50M 10-K · filed 2019-03-22 | |
| 2017-12-31 | -$26.27M 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$15.84M 10-K · filed 2018-03-15 | |
| 2015-12-31 | -$31.38M 10-K · filed 2017-03-16 | -$31.33M 10-K · filed 2016-03-10 |
| 2014-12-31 | -$22.24M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |